All In Biotech

Drug Trial Radar · NCT02013544

Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause

Last checked: Nov 20, 2026Latest source record: Jun 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 558 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

558

Actual

Start

Feb 2014

Primary completion

Jan 2015

Study completion Feb 2015

Sponsor

Lead sponsor
EndoCeutics Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on symptoms of vulvovaginal atrophy due to menopause and to collect further data on subjects exposed to intravaginal DHEA in order to meet the ICH E1 guideline requirements.

Conditions

  • Vaginal Atrophy

Interventions

  • PlaceboDrug

  • Prasterone (DHEA)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 12 in Percentage of Superficial Cells in the Maturation Index of the Vaginal SmearTime frame: Baseline and Week 12
  2. Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal SmearTime frame: Baseline and Week 12
  3. Change From Baseline to Week 12 in Vaginal pHTime frame: Baseline and Week 12
  4. Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of DyspareuniaTime frame: Baseline and Week 12

Locations

38 sites in 2 countries. Site status is shown where the registry gives one.

  • EndoCeutics site # 39

    Montgomery, Alabama

  • EndoCeutics site # 14

    Tucson, Arizona

  • EndoCeutics site # 21

    Sacramento, California

  • EndoCeutics site # 83

    San Diego, California

  • EndoCeutics site # 30

    San Diego, California

  • EndoCeutics site # 36

    Denver, Colorado

  • EndoCeutics site # 52

    Denver, Colorado

  • EndoCeutics site # 45

    Boynton Beach, Florida

  • EndoCeutics site # 60

    Lake Worth, Florida

  • EndoCeutics site # 54

    North Miami, Florida

  • EndoCeutics site # 80

    West Palm Beach, Florida

  • EndoCeutics site # 23

    Atlanta, Georgia

  • EndoCeutics site # 55

    Wichita, Kansas

  • EndoCeutics site # 86

    Louisville, Kentucky

  • EndoCeutics site # 27

    Lutherville, Maryland

  • EndoCeutics site # 87

    Lawrenceville, New Jersey

  • EndoCeutics site # 81

    Plainsboro, New Jersey

  • EndoCeutics site # 05

    Cleveland, Ohio

  • EndoCeutics site # 15

    Columbus, Ohio

  • EndoCeutics site # 75

    Philadelphia, Pennsylvania

  • EndoCeutics site # 84

    Corpus Christi, Texas

  • EndoCeutics site # 82

    Houston, Texas

  • EndoCeutics site # 03

    Norfolk, Virginia

  • EndoCeutics site # 76

    Seattle, Washington

  • EndoCeutics site # 85

    Burlington, Ontario, Canada

  • EndoCeutics site # 69

    Corunna, Ontario, Canada

  • EndoCeutics site # 68

    Sarnia, Ontario, Canada

  • EndoCeutics site # 73

    Waterloo, Ontario, Canada

  • EndoCeutics site # 04

    Drummondville, Quebec, Canada

  • EndoCeutics site # 12

    Montreal, Quebec, Canada

  • EndoCeutics site # 79

    Pointe-Claire, Quebec, Canada

  • EndoCeutics site # 02

    Québec, Quebec, Canada

  • EndoCeutics site # 01

    Québec, Quebec, Canada

  • EndoCeutics site # 77

    Québec, Quebec, Canada

  • EndoCeutics site # 78

    Québec, Quebec, Canada

  • EndoCeutics site # 18

    Saint Romuald, Quebec, Canada

  • EndoCeutics site # 74

    Sherbrooke, Quebec, Canada

  • EndoCeutics site # 67

    Victoriaville, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.